HUDDINGS, Sweden, November 21, 2022 /PRNewswire/ — XNK Therapeutics AB (“XNK”) announced today that it will continue its partnership with Karolinska Cell Therapy Center’s manufacturing unit Vecura, led by Pontus Blomberg and Veronique Chotteau’s cell technology group from the Swedish Royal Institute of Technology as part of a collaboration within the center of excellence for advanced bioproduction through continuous processing, AdBIOPRO.

“The innovation agency Vinnova, which is funded by the Swedish government, has granted the AdBIOPRO competence center a five-year extension. This means that we can continue our part of the collaboration within AdBIOPRO together with the group of Vecura and Veronique Chotteau from KTH,” said Anna-Karin Maltai’s CSO at XNK Therapeutika. “Working with AdBIOPRO over the years has helped improve our manufacturing process and enable scale-out to reach more patients. This expansion of the investment is very valuable for XNK as it also brings in complementary biomanufacturing talent .”

XNK’s continued work with AdBIOPRO, under Per Henrik Holmqvist Leadership, will enable further in-depth characterization of natural killer (NK) cell cultures at different process parameters, contribute to the advancement of production techniques and investigate increased automation for more efficient large-scale production.

For more information, please contact:

Johan Liwing, CEO, XNK Therapeutics
Phone: +46 706 70 36 75
E-mail: johan.liwing@xnktherapeutics.com

About XNK Therapeutics AB

XNK Therapeutics is a clinical-stage immunotherapy company focused on the prevention and treatment of cancer through the development of novel NK cell-based therapies. The company is a leader in the development of autologous NK cell-based products using its proprietary technology platform. The Company’s platform technology and lead investigational candidate are specifically designed to fight cancer, including situations where allogeneic cell products are not readily applicable. The goal of the company…